The term Aptamer refers to small molecules that can bind specific sides of their target molecule. These molecules can be based on nucleic acids (single-stranded DNA/ RNA) or peptides (peptide-aptamers, PA). They offer great flexibility in terms of design and development, and their binding specificity and selectivity has made them an ideal alternative to antibodies (1). These features have made nucleic-acids aptamers increasingly popular in research, diagnostics, and drug development (2; 3; 4).
Nucleic-acids aptamers bind their targets using larger interaction surfaces, compared to PAs. This is due to the fact that PAs consist of 15-20 amino-acids peptides embedded into stable protein scaffolds. Therefore, the interaction surface between PA and their target is restricted to the 15-20 amino-acids of the PA variable region (1).
A summarized list of features to consider when ordering aptamers is shown in the table below:
|Nucleic Acids Aptamers||Peptide-Aptamers|
|Form flexible 3D structures, with RNA Aptamers forming particularly diverse conformations||3D Conformation is constrained by the protein scaffold|
|Bind target using their entire length||Binding region is restricted to the 15-20 amino-acids of the variable region|
At metabion, we always strive to assist our customers with their cutting-edge scientific applications. We are expert in oligonucleotide synthesis and we are glad to provide you with a fully customized solution for aptamer synthesis, of course of best quality!
Main features of our Aptamers:
- All our Aptamers are scrupulously quality-controlled via Mass-Check analysis before release.
- RNA Aptamers are HPLC-purified and mass-checked for highest quality.
- You can choose among a seasoned selection of modifications from our DNA and RNA portfolio.
For more information and a quotation, contact us at email@example.com
1. S. Reverdatto, D. S. Burz, A. Shekhtman. Peptide Aptamers: Development and Applications. Curr Top Med Chem. 15, 2015, Vol. 12, 1082-1101.
2. Jung Wook Huh, Sung Chun Kim, Insuk Sohn, Sin-Ho Jung, and Hee Cheol Kim. Serum protein profiling using an aptamer array predicts clinical outcomes of stage IIA colon cancer: A leave-one-out crossvalidation. Oncotarget. 7, 2016, Vol. 13, 16338–16348.
3. Jiehua Zhou, John Rossi. Aptamers as targeted therapeutics: current potential and challenges. Nature Reviews Drug Discovery. doi:10.1038/nrd.2016.199, 2016.
4. Franziska Pfeiffer, Günter Mayer. Selection and Biosensor Application of Aptamers for Small Molecules. Front Chem. . 4, 2016, Vol. 25, 10.3389/fchem.2016.00025.